Repligen (RGEN) Competitors $118.90 +0.81 (+0.68%) As of 01:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGEN vs. TECH, A, DHR, TMO, BIIB, UTHR, INCY, NBIX, EXEL, and BMRNShould you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Bio-Techne (TECH), Agilent Technologies (A), Danaher (DHR), Thermo Fisher Scientific (TMO), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector. Repligen vs. Its Competitors Bio-Techne Agilent Technologies Danaher Thermo Fisher Scientific Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk. Do insiders and institutionals believe in TECH or RGEN? 99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 3.9% of Bio-Techne shares are owned by company insiders. Comparatively, 1.2% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, TECH or RGEN? Bio-Techne has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-Techne$1.16B6.93$168.10M$0.8262.52Repligen$634.44M10.53-$25.51M-$0.45-264.23 Which has more volatility & risk, TECH or RGEN? Bio-Techne has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Do analysts rate TECH or RGEN? Bio-Techne currently has a consensus price target of $70.00, indicating a potential upside of 36.55%. Repligen has a consensus price target of $170.75, indicating a potential upside of 43.60%. Given Repligen's stronger consensus rating and higher probable upside, analysts clearly believe Repligen is more favorable than Bio-Techne.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Techne 0 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50Repligen 0 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.69 Is TECH or RGEN more profitable? Bio-Techne has a net margin of 10.89% compared to Repligen's net margin of -3.93%. Bio-Techne's return on equity of 13.17% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Bio-Techne10.89% 13.17% 10.17% Repligen -3.93%4.53%3.17% Does the media refer more to TECH or RGEN? In the previous week, Bio-Techne had 14 more articles in the media than Repligen. MarketBeat recorded 23 mentions for Bio-Techne and 9 mentions for Repligen. Repligen's average media sentiment score of 1.10 beat Bio-Techne's score of 0.89 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 11 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBio-Techne beats Repligen on 11 of the 16 factors compared between the two stocks. Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGEN vs. The Competition Export to ExcelMetricRepligenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.68B$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-264.2320.3528.6119.64Price / Sales10.53304.32437.49188.30Price / Cash39.0543.1536.0257.93Price / Book3.387.718.185.63Net Income-$25.51M-$55.11M$3.23B$257.73M7 Day Performance-8.41%0.68%-0.25%0.07%1 Month Performance-5.70%8.22%5.40%8.32%1 Year Performance-11.92%-2.64%26.35%13.78% Repligen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGENRepligen4.6307 of 5 stars$118.91+0.7%$170.75+43.6%-3.7%$6.68B$634.44M-264.231,778Positive NewsTECHBio-Techne4.8678 of 5 stars$51.53-3.0%$72.00+39.7%-33.4%$8.08B$1.16B62.843,100News CoverageAAgilent Technologies4.8112 of 5 stars$119.21-1.8%$140.92+18.2%-13.6%$33.86B$6.51B29.4317,900DHRDanaher4.97 of 5 stars$199.60-1.8%$248.61+24.6%-21.7%$142.85B$23.88B38.7663,000Positive NewsUpcoming EarningsTMOThermo Fisher Scientific4.9917 of 5 stars$418.76-2.5%$604.05+44.2%-23.1%$158.08B$42.88B24.56125,000Positive NewsUpcoming EarningsDividend AnnouncementBIIBBiogen4.779 of 5 stars$130.13-2.1%$188.48+44.8%-42.5%$19.07B$9.68B12.857,605Analyst RevisionUTHRUnited Therapeutics4.9872 of 5 stars$290.39-1.4%$386.15+33.0%-10.4%$13.10B$2.88B11.591,305Positive NewsInsider TradeINCYIncyte4.6832 of 5 stars$67.27-1.7%$74.53+10.8%+6.2%$13.02B$4.24B210.232,617Analyst ForecastAnalyst RevisionNBIXNeurocrine Biosciences4.4897 of 5 stars$127.88-1.0%$162.00+26.7%-11.0%$12.66B$2.36B43.351,800Trending NewsAnalyst RevisionEXELExelixis4.7509 of 5 stars$44.16-4.3%$43.56-1.4%+95.4%$12.04B$2.17B20.071,147Analyst ForecastBMRNBioMarin Pharmaceutical4.9843 of 5 stars$57.41-0.2%$93.61+63.1%-33.1%$11.01B$2.85B21.343,040Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Bio-Techne Alternatives Agilent Technologies Alternatives Danaher Alternatives Thermo Fisher Scientific Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGEN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
